(9ci)-n,1-二甲基-1H-咪唑-4-羧酰胺 | 129993-50-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (9ci)-n,1-二甲基-1H-咪唑-4-羧酰胺
• 英文名称: 1-methylimidazole-4-carboxymethylamide
• 英文别名: N,1-dimethyl-1H-imidazole-4-carboxamide；N,1-dimethylimidazole-4-carboxamide
• CAS: 129993-50-6
• 化学式: C₆H₉N₃O
• 分子量: 139.157
• InChiKey: VDIARKOFXBRNIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  甲胺 、 1-甲基咪唑-4-甲酸乙酯 以 水 为溶剂， 反应 1.0h， 以85%的产率得到(9ci)-n,1-二甲基-1H-咪唑-4-羧酰胺
  参考文献：
  名称：

  Selective alkylation of imidazole-4(5)-carboxamides

  摘要：

  DOI：

  10.1007/bf00497210

文献信息

• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：Genentech, Inc.

  公开号：US20150065522A1

  公开（公告）日：2015-03-05

  The present invention relates to compounds formula (I): and to salts thereof, wherein R 1 -R 4 and A have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of histone demethylases, such as KDM5. Also included are pharmaceutically acceptable compositions comprising the compounds of the present invention and methods of using said compositions in the treatment of various disorders.

  本发明涉及化合物的化学式（I）及其盐，其中R1-R4和A具有规范中定义的任何值，以及这些化合物的组合物和用途。这些化合物可用作组蛋白去甲基化酶的抑制剂，如KDM5。还包括包含本发明化合物的药用可接受组合物，以及使用这些组合物治疗各种疾病的方法。
• DIHYDROCHROMENE DERIVATIVE
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US20200216461A1

  公开（公告）日：2020-07-09

  The present invention relates to the compound of formula (I) wherein R 1A , R 1B , R 1C , and R 1D are hydrogen atom, etc., R 2A and R 2B are hydrogen atom, etc., R 3A , R 3B , R 3C , and R 3D are hydrogen atom, etc., L is bond, etc., V is C 1-6 alkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents.

  本发明涉及公式（I）的化合物，其中R1A，R1B，R1C和R1D是氢原子等，R2A和R2B是氢原子等，R3A，R3B，R3C和R3D是氢原子等，L是键等，V是C1-6烷基，Q是可选取代咪唑或其药学上可接受的盐，作为一种新的抗肿瘤剂，针对被认为与恶性肿瘤的持续增殖、转移或复发以及抗肿瘤剂的耐药性密切相关的CSCs。
• SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE
  申请人：Emelen Van Kristof

  公开号：US20070142393A1

  公开（公告）日：2007-06-21

  This invention comprises the novel compounds of formula (I) wherein n, m, t, R 1 , R 2 , R 3 , R 4 , L, Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.

  这项发明涉及公式（I）中的新化合物，其中n，m，t，R1，R2，R3，R4，L，Q，X，Y，Z和具有定义的含义，具有组织脱乙酰化酶抑制酶活性；它们的制备，包含它们的组合物以及它们作为药物的用途。
• Sulfonyl-Derivatives as Novel Inhibitors or Histone Deacetylase
  申请人：Van Emelen Kristof

  公开号：US20080108601A1

  公开（公告）日：2008-05-08

  This invention comprises the novel compounds of formula (I) wherein n, m, t, R 1 , R 2 , R 3 , R 4 , L, Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.

  这项发明包括具有组成式（I）的新化合物，其中n，m，t，R1，R2，R3，R4，L，Q，X，Y，Z和具有定义的含义，具有组蛋白去乙酰化酶抑制酶活性；它们的制备，含有它们的组合物以及它们作为药物的用途。
• Sulfonyl-Derivatives as Novel or Histone Deacetylase
  申请人：Van Emelen Kristof

  公开号：US20100240639A1

  公开（公告）日：2010-09-23

  This invention comprises the novel compounds of formula (I) wherein n, m, t, R 1 , R 2 , R 3 , R 4 , L, Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.

  这项发明涉及公式(I)的新型化合物，其中n、m、t、R1、R2、R3、R4、L、Q、X、Y、Z和具有定义的含义，具有组蛋白去乙酰化酶抑制酶活性；它们的制备，含有它们的组合物以及它们作为药物的用途。